Filing Flows

Filing Flows › Companies › Jupiter Neurosciences › Cash flow

Jupiter Neurosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.3M in Q2 2026 · −$7.2M over twelve months

Operating cash flow−$2.3M
Free cash flow−$2.3M

Analysis

In Q2 2026, Jupiter Neurosciences generated −$2.3M of operating cash flow. That is $1.5M less than in Q2 2025 (−$828K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$7.2M; the largest uses were operating cash flow ($7.2M); the cash balance fell by $356K.

Operating cash flow was −$2.3M against net income of −$2.3M. The largest differences: stock-based pay +$491K, payables +$444K, inventory +$13K.

Free cash flow

Jupiter Neurosciences: free cash flow by quarterJupiter Neurosciences: free cash flow by quarter−$43KQ3 2024−$3.7MQ4 2024−$1.1MQ1 2025−$828KQ2 2025−$1.2MQ3 2025−$2.4MQ4 2025−$1.4MQ1 2026−$2.3MQ2 2026
Operating cash flow less capital spending.
Jupiter Neurosciences: operating cash flow against capital spendingJupiter Neurosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$43K$0Q3 2024−$3.7M$0Q4 2024−$1.1M$0Q1 2025−$828K$0Q2 2025−$1.2M$0Q3 2025−$2.4M$0Q4 2025−$1.4M$0Q1 2026−$2.3M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.3M, Capital spending $0.

Capital allocation, year by year

Jupiter Neurosciences: where the cash came from (up) and went (down), by fiscal yearJupiter Neurosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2023: Operating cash flow −$481KFY2023: Net borrowing $390KFY2023: Shares issued $55K$445KFY2023FY2024: Operating cash flow −$3.9MFY2024: Net borrowing −$12KFY2024: Shares issued $150K$150KFY2024FY2025: Operating cash flow −$5.4MFY2025
Over these 3 years operating cash flow totalled −$9.8M; the largest uses were operating cash flow ($9.8M) and net borrowing ($12K). Cash-flow statements as filed.

Where the cash came from and went

Jupiter Neurosciences: sources (+) and uses (−) of cash, Q2 2026Jupiter Neurosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.3MOther financing$1.5MCash drawn (+) / kept (−)$841K
Jupiter Neurosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Jupiter Neurosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$7.2MNot reconciled$6.9MCash drawn (+) / kept (−)$356K

From profit to cash

Jupiter Neurosciences: net income to operating cash flow, Q2 2026Jupiter Neurosciences: net income to operating cash flow, Q2 2026Net income−$2.3MStock-based pay$491KReceivables−$10KInventory$13KPayables$444KDeferred revenue$1KPrepaid and other assets$4KOperating cash flow−$2.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.3M——$841K−$2.3M
Q1 2026−$1.4M$472K$6K$1.4M−$1.4M
Q4 2025−$2.4M——−$3.1M−$2.4M
Q3 2025−$1.2M——$1.2M−$1.2M
Q2 2025−$828K——$828K−$828K
Q1 2025−$1.1M——$1.1M−$1.1M
Q4 2024−$3.7M$2K$100K−$3.8M−$3.7M
Q3 2024−$43K$28K—$15K−$43K

Jupiter Neurosciences: income statement and cash flow

Jupiter Neurosciences, Q2 2026: revenue $24K. The chart follows the revenue to costs, profit and cash.

Jupiter Neurosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.